Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous myoblast graft is an experimental cell therapy developed by the University Hospital, Caen, for the treatment of oculopharyngeal muscular dystrophy (OPMD). The procedure involves harvesting healthy muscle progenitor cells (myoblasts) from the patient's own unaffected muscles, such as the quadriceps or sternocleidomastoid, and expanding them in vitro. These expanded cells are then injected into the affected muscles, specifically the levator palpebrae superioris to treat ptosis or the pharyngeal muscles to treat dysphagia. The therapy aims to regenerate or reinforce the weakened muscle tissue, thereby restoring muscle function and improving clinical symptoms associated with the genetic disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous myoblast graft.